ifnlr1 Antibody, HRP conjugated

Introduction to IFNLR1 Antibody

IFNLR1 (Interferon Lambda Receptor 1) is a critical component of the type III interferon (IFN-λ) signaling pathway, which mediates antiviral and immunomodulatory responses in epithelial and immune cells . An IFNLR1 antibody conjugated to horseradish peroxidase (HRP) is a specialized immunoassay tool designed to detect and quantify IFNLR1 protein expression in research settings. HRP conjugation enables sensitive visualization via enzymatic reactions, commonly used in techniques like Western blot (WB), immunohistochemistry (IHC), and enzyme-linked immunosorbent assays (ELISA) . While the provided sources do not explicitly describe HRP-conjugated IFNLR1 antibodies, they highlight monoclonal and polyclonal antibodies targeting IFNLR1, offering insights into their development, validation, and applications .

3.1. Role in Hepatitis B Virus (HBV) Studies

• IFNLR1 Isoform-Specific Effects: Overexpression of IFNLR1 isoform 1 (full-length) in induced pluripotent stem cell-derived hepatocytes (iHeps) enhanced IFN-λ3-induced antiviral gene expression (e.g., MX1, APOBEC3G) and suppressed HBV replication . Antibodies like HLR14 were critical in validating IFNLR1 surface expression during these studies .

• Mechanistic Insights: IFNLR1 isoform 2 (truncated intracellular domain) and isoform 3 (secreted) showed reduced capacity to inhibit HBV replication, highlighting the importance of isoform-specific antibody validation .

3.2. Immunomodulatory Functions in Herpes Simplex Virus (HSV)

• Neutrophil Regulation: In Ifnlr1⁻/⁻ mice, IFNLR1 antibodies helped identify increased neutrophil recruitment during HSV-1 infection. IFN-λ signaling via IFNLR1 in keratinocytes suppressed CXCL9-mediated neutrophil infiltration, reducing immunopathology .

Challenges in IFNLR1 Antibody Development

• Isoform Specificity: IFNLR1 has three transcriptional variants (isoforms 1–3), necessitating antibodies that distinguish full-length vs. truncated forms .

• Low Surface Expression: IFNLR1 protein levels on hepatocytes and immune cells are often low, requiring high-sensitivity antibodies like HLR14 for reliable detection .

Future Directions

While HRP-conjugated IFNLR1 antibodies are not explicitly detailed in the provided sources, existing antibodies (e.g., HLR14, 601106) could be adapted for HRP-based assays to enhance signal detection in WB or ELISA. Future studies should focus on:

• Developing isoform-specific HRP conjugates to dissect IFN-λ signaling mechanisms.

• Optimizing antibodies for translational research in chronic viral infections (HBV, HSV) and inflammatory diseases .